AKT1 and neoplasm: Loss of function alterations have been shown for negative modulators of MAPK/ERK pathway such as DUSP4, NF1, SPRY and Sef [13–16], while reduced expression of PTEN tumor-suppressor as essential regulator of PI3K/AKT signaling has been documented in 33% of breast tumors [17].